Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

• Published in: British journal of cancer Vol. 111; no. 5; pp. 874 - 882
• Main Authors: Valenzuela, M, Glorieux, C, Stockis, J, Sid, B, Sandoval, J M, Felipe, K B, Kviecinski, M R, Verrax, J, Calderon, P Buc
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.08.2014; Nature Publishing Group
• Subjects: 631/92/609; 692/699/67/1990/283/1897; 692/700/565/1436/1437; Acids; Antioxidants; Arsenic; Arsenicals - pharmacology; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Cell Survival - drug effects; Cytotoxicity; Drug Resistance; Drug Synergism; Drugs; Epidemiology; Glutathione - metabolism; Hematologic and hematopoietic diseases; Heme Oxygenase-1 - metabolism; HL-60 Cells; Humans; Leukemia; Leukemia, Promyelocytic, Acute - drug therapy; Leukemia, Promyelocytic, Acute - metabolism; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical research; Medical sciences; Molecular Medicine; Mortality; NF-E2-Related Factor 2 - metabolism; Oncology; Oxidation; Oxides - pharmacology; Receptors, Retinoic Acid - genetics; Remission (Medicine); Retinoic Acid Receptor alpha; Translational Therapeutics; Tretinoin - pharmacology; Tumor Cells, Cultured; Tumors; Belgium; Chile; United States > US; all; retinoic acid; arsenic trioxide; Nrf2; HO-1; GSH; acute promyelocytic leukaemia; Antineoplastic agent; Promyelocytic leukemia; all-trans retinoic acid; Acute myelogenous leukemia; Enzyme; Acute; Retinoid; Heme oxygenase (decyclizing); Cytotoxicity; Arsenic trioxide; Malignant hemopathy; Biological activity; Cancerology; Antiacneic agent; Oxidoreductases; Retinoic acid; Cell; Cancer; M3 acute myelocytic leukemia; Tretinoin
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2014.380

Background: Standard therapy for acute promyelocytic leukaemia (APL) includes retinoic acid (all- trans retinoic acid (ATRA)), which promotes differentiation of promyelocytic blasts. Although co-administration of arsenic trioxide (ATO) with ATRA has emerged as an effective option to treat APL, the molecular basis of this effect remains unclear. Methods: Four leukaemia cancer human models (HL60, THP-1, NBR4 and NBR4-R2 cells) were treated either with ATO alone or ATO plus ATRA. Cancer cell survival was monitored by trypan blue exclusion and DEVDase activity assays. Gene and protein expression changes were assessed by RT-PCR and western blot. Results: ATO induced an antioxidant response characterised by Nrf2 nuclear translocation and enhanced transcription of downstream target genes (that is, HO-1, NQO1, GCLM, ferritin). In cells exposed to ATO plus ATRA, the Nrf2 nuclear translocation was prevented and cytotoxicity was enhanced. HO-1 overexpression reversed partially the cytotoxicity by ATRA-ATO in HL60 cells. The inhibitory effects of ATRA on ATO-mediated responses were not observed in either the ATRA-resistant NB4-R2 cells or in NB4 cells pre-incubated with the RAR α antagonist Ro-41-52-53. Conclusions: The augmented cytotoxicity observed in leukaemia cells following combined ATO-ATRA treatment is likely due to inhibition of Nrf2 activity, thus explaining the efficacy of combined ATO-ATRA treatment in the APL therapy.